Pure Global

Effect of a Food Supplementation With a Combined Food Supplement on Lipid Pattern, Indexes of Non-alcoholic Fatty Liver Disease and Systemic Inflammation - Trial NCT06247137

Access comprehensive clinical trial information for NCT06247137 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Bologna and is currently Completed. The study focuses on Hypercholesterolemia. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06247137
Completed
dietary supplement
Trial Details
ClinicalTrials.gov โ€ข NCT06247137
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Effect of a Food Supplementation With a Combined Food Supplement on Lipid Pattern, Indexes of Non-alcoholic Fatty Liver Disease and Systemic Inflammation
Evaluation of the Effect of a Food Supplementation With a Combined Food Supplement on Lipid Pattern, Indexes of Non-alcoholic Fatty Liver Disease and Systemic Inflammation in Healthy Subjects With Suboptimal LDL-C Levels: a Two-arm Double-blind, Placebo- Controlled, Randomized, Clinical Trial

Study Focus

Hypercholesterolemia

Dietary Supplement

Interventional

dietary supplement

Sponsor & Location

University of Bologna

Bologna, Italy

Timeline & Enrollment

N/A

Apr 01, 2022

Dec 30, 2022

90 participants

Primary Outcome

LDL-cholesterolemia reduction from baseline and between groups

Summary

Several controlled interventional studies have shown that there is a close correlation
 between cholesterol reduction and cardiovascular risk; in fact, reductions in the plasma
 concentration of total cholesterol and LDL, obtained through lifestyle modification or
 specific drugs, result in reductions in the incidence of major coronary events. The
 effectiveness of these interventions has been demonstrated both in subjects in primary
 prevention and in subjects in secondary prevention.
 
 Based on this evidence, the National Cholesterol Education Program (NCEP) has defined in the
 ATP III report the target values of LDL cholesterol (C-LDL) to be reached with interventions
 on food and / or pharmacological habits to perform an effective cardiovascular prevention.
 
 Although the atherogenic action of hypercholesterolemia is largely attributable to a direct
 damage exerted on vascular endothelium, recent studies suggest that the activation of a
 low-grade systemic pro-inflammatory state, typical of the patient with cardiovascular risk
 factors, does also play a role in the determinism of endothelial damage and atheroma
 degeneration of the arteries. It is believed that this systemic inflammation, as documented
 by the determination of some humoral signs of inflammation (e.g. C-reactive protein,
 interleukin-6, tumor necrosis factor-ฮฑ), may further contribute to an increase of
 cardiovascular risk.
 
 The inflammatory state can modulate the atherosclerotic process at various levels,
 determining endothelial activation, promoting leukocyte chemotaxis in the sub-intimal space
 of the arterial wall and therefore the formation of an atheromatous plaque rich in
 inflammatory cells; the latter represents the lesion responsible for the vast majority of the
 coronary and cerebrovascular events observed in subjects with cardiovascular risk factors.

ICD-10 Classifications

Pure hypercholesterolaemia
Lipoprotein deficiency
Hyperglycaemia, unspecified
Disorders of lipoprotein metabolism and other lipidaemias
Other disorders of lipoprotein metabolism

Data Source

ClinicalTrials.gov

NCT06247137

Non-Device Trial